Roche says once-a-month anaemia treatment Mircera as effective as current drugs |
|
|
|
Published
:
Fri, 19 Oct 2007 07:12
|
ZURICH (Thomson Financial) - Roche Holdings AG said a study has shown that its anaemia treatment Mircera, administered once a month, is as effective as currently available drugs, which patients have to take more frequently.Mircera is the first drug that directly converts patients from frequent dosing to once-monthly dosing, the Swiss pharma group said.The so-called Maxima study involving 673 patients with stable chronic renal anaemia found that haemoglobin levels of those given Mircera once every four weeks were maintained on similar concentrations as other treatments which have to be administered one to three times a week.Chronic renal anaemia is a complication arising from chronic kidney disease which affects approximately one in ten of the general population.huimin.neo@thomson.comjmt/hmn/jfrCOPYRIGHTCopyright Thomson Financial News Limited 2007. All rights reserved.The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.
|
|
|
|
Print this Story
Roche 9-mths sales slow due to weaker Tamiflu orders; confirms guidance UPDATE 